货品编号： Invitrogen.TCR2720 品牌：Invitrogen 品名： Human TCR Vgamma9 FITC-lateled Mab

产品描述：

Product Specific Information TCR2720 targets TCR V gamma 9 in FACS applications and shows reactivity with Human, and Non-human primate samples.

The TCR2720 immunogen is human TCR Vgamma9.

Background/Target Information The ability of T cell receptors (TCR) to discriminate foreign from self-peptides presented by major histocompatibility complex (MHC)

class II molecules is essential for an effective adaptive immune response. TCR recognition of self-peptides has been linked to

autoimmune disease. Mutant self-peptides have been associated with tumors. Engagement of TCRs by a family of bacterial toxins

know as superantigens has been responsible for toxic shock syndrome. Autoantibodies to V beta segments of T cell receptors have

been isolated from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The autoantibodies block TH1-

mediated inflammatory autodestructive reactions and are believed to be a method by which the immune system compensates for

disease (ref5). T Cell and TCR Diversity Most human T cells express the TCR alpha-beta and either CD4 or CD8 molecule (single

positive, SP). A small number of T cells lack both CD4 and CD8 (double negative, DN). Increased percentages of alpha-beta DN T

cells have been identified in some autoimmune and immunodeficiency disorders. Gamma-delta T cells are primarily found within the

epithelium. They show less TCR diversity and recognize antigens differently than alpha-beta T cells. Subsets of gamma-delta T cells

have shown antitumor and immunoregulatory activity.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.